COVID-19 相关肝脏疾病：病因、治疗与预后。
Liver diseases in COVID-19: Etiology, treatment and prognosis.
机构信息
State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China.
Department of Pathology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
出版信息
World J Gastroenterol. 2020 May 21;26(19):2286-2293. doi: 10.3748/wjg.v26.i19.2286.
Abstract
In December 2019, a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China causing coronavirus disease-2019 (COVID-19). Numerous studies have shown varying degrees of liver damage in patients infected with SARS-CoV-2. However, in previous case studies of COVID-19, the exact cause of liver injury has not been clearly elucidated, nor is there clear evidence of the interaction between liver injury and COVID-19. This study will analyze the causes of liver injury in COVID-19 and the influence of liver-related complications on the treatment and prognosis of COVID-19.
摘要
2019 年 12 月，一种新型冠状病毒——严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）在中国武汉被发现，引发了 2019 年冠状病毒病（COVID-19）。大量研究表明，感染 SARS-CoV-2 的患者存在不同程度的肝损伤。然而，在之前 COVID-19 的病例研究中，肝损伤的确切原因尚未阐明，也没有明确的证据表明肝损伤与 COVID-19 之间存在相互作用。本研究将分析 COVID-19 中肝损伤的原因，以及肝相关并发症对 COVID-19 治疗和预后的影响。
相似文献
1
Liver diseases in COVID-19: Etiology, treatment and prognosis.COVID-19 相关肝脏疾病：病因、治疗与预后。
World J Gastroenterol. 2020 May 21;26(19):2286-2293. doi: 10.3748/wjg.v26.i19.2286.
2
Etiology and management of liver injury in patients with COVID-19.新型冠状病毒肺炎患者肝损伤的病因和处理。
World J Gastroenterol. 2020 Aug 28;26(32):4753-4762. doi: 10.3748/wjg.v26.i32.4753.
3
COVID-19 and the liver: What do we know after six months of the pandemic?COVID-19 与肝脏：大流行六个月后我们了解多少？
Ann Hepatol. 2020 Nov-Dec;19(6):590-591. doi: 10.1016/j.aohep.2020.09.001. Epub 2020 Sep 18.
4
Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review.新型冠状病毒肺炎的胃肠道和肝脏表现：全面综述。
World J Gastroenterol. 2020 May 21;26(19):2323-2332. doi: 10.3748/wjg.v26.i19.2323.
5
[The protocol for prevention, diagnosis and treatment of liver injury in coronavirus disease 2019].[新型冠状病毒肺炎肝损伤防治专家共识]
Zhonghua Gan Zang Bing Za Zhi. 2020 Mar 20;28(3):217-221. doi: 10.3760/cma.j.cn501113-20200309-00095.
6
The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis.新型冠状病毒病患者的肝损伤和胃肠道症状：系统评价和荟萃分析。
Clin Res Hepatol Gastroenterol. 2020 Oct;44(5):653-661. doi: 10.1016/j.clinre.2020.04.012. Epub 2020 May 12.
7
Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study.美国已有肝病患者中2019冠状病毒病的临床特征与转归：一项多中心研究网络研究
Gastroenterology. 2020 Aug;159(2):768-771.e3. doi: 10.1053/j.gastro.2020.04.064. Epub 2020 May 4.
8
COVID-19 pandemic: Its impact on liver disease and liver transplantation.COVID-19 大流行：对肝病和肝移植的影响。
World J Gastroenterol. 2020 Jun 14;26(22):2987-2999. doi: 10.3748/wjg.v26.i22.2987.
9
Predictor of poor prognosis of COVID-19 patients - liver injury.COVID-19患者预后不良的预测指标——肝损伤。
Expert Rev Gastroenterol Hepatol. 2020 Oct;14(10):873-876. doi: 10.1080/17474124.2020.1793670. Epub 2020 Jul 30.
10
The clinical manifestations and management of COVID-19-related liver injury.新型冠状病毒肺炎相关肝损伤的临床表现与处理
J Formos Med Assoc. 2020 Jun;119(6):1016-1018. doi: 10.1016/j.jfma.2020.04.020. Epub 2020 Apr 24.
引用本文的文献
1
Ferroptosis and mitochondrial ROS are central to SARS-CoV-2-induced hepatocyte death.铁死亡和线粒体活性氧是新冠病毒诱导肝细胞死亡的关键因素。
Front Cell Infect Microbiol. 2025 Aug 11;15:1625928. doi: 10.3389/fcimb.2025.1625928. eCollection 2025.
2
The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment, and Management of Suspected Acute Drug-Induced Liver Injury Occurring during Clinical Trials: Consensus Recommendations from the IQ DILI Initiative.2019年冠状病毒病（COVID-19）及COVID-19疫苗接种对临床试验期间疑似急性药物性肝损伤的检测、评估及管理的影响：IQ药物性肝损伤倡议组织的共识建议
Drug Saf. 2025 Aug 5. doi: 10.1007/s40264-025-01591-0.
3
Impact of underlying diseases and complications on COVID-19 mortality in South Korea: analysis of national health insurance service data.基础疾病及并发症对韩国新冠疫情死亡率的影响：基于国民健康保险服务数据的分析
Arch Public Health. 2025 Jan 23;83(1):20. doi: 10.1186/s13690-025-01509-3.
4
Assessment of abnormal liver function tests and associated factors among COVID-19-infected patients in Addis Ababa, Ethiopia, 2022: a facility-based comparative cross-sectional study.2022 年埃塞俄比亚亚的斯亚贝巴感染 COVID-19 的患者异常肝功能检测及相关因素评估：基于机构的比较性横断面研究。
BMJ Open. 2024 Sep 10;14(9):e076647. doi: 10.1136/bmjopen-2023-076647.
5
Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management.新型冠状病毒肺炎相关肝损伤的研究进展：病因、诊断与治疗。
Inflammopharmacology. 2024 Oct;32(5):2649-2680. doi: 10.1007/s10787-024-01535-7. Epub 2024 Aug 10.
6
The Potential Mechanisms Behind Adverse Effect of Coronavirus Disease-19 on Heart and Liver Damage: A Review.新型冠状病毒病对心脏和肝脏损伤的潜在作用机制：综述。
Ethiop J Health Sci. 2024 Jan;34(1):85-100. doi: 10.4314/ejhs.v34i1.10.
7
Hepatitis B Reactivation and Liver Failure Because of COVID-19 Infection.COVID-19感染导致的乙型肝炎再激活和肝衰竭
ACG Case Rep J. 2024 Jun 27;11(7):e01397. doi: 10.14309/crj.0000000000001397. eCollection 2024 Jul.
8
Stability analysis and optimal control of a fractional-order generalized SEIR model for the COVID-19 pandemic.COVID-19大流行的分数阶广义SEIR模型的稳定性分析与最优控制
Appl Math Comput. 2023 Jun 27:128210. doi: 10.1016/j.amc.2023.128210.
9
Age-dependent immune responses in COVID-19-mediated liver injury: focus on cytokines.COVID-19 介导的肝损伤中的年龄依赖性免疫反应：聚焦细胞因子。
Front Endocrinol (Lausanne). 2023 Aug 15;14:1139692. doi: 10.3389/fendo.2023.1139692. eCollection 2023.
10
Patient Perceptions and Satisfaction With Virtual Clinics During the COVID-19 Pandemic: A Cross-Sectional Study.COVID-19大流行期间患者对虚拟诊所的认知与满意度：一项横断面研究
Cureus. 2023 Jul 25;15(7):e42450. doi: 10.7759/cureus.42450. eCollection 2023 Jul.
本文引用的文献
1
Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2.新型冠状病毒（SARS-CoV-2）受体ACE2的单细胞RNA表达谱分析
Am J Respir Crit Care Med. 2020 Sep 1;202(5):756-759. doi: 10.1164/rccm.202001-0179LE.
2
Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China.中国广州 2019 年冠状病毒病病例的免疫病理学特征。
Immunology. 2020 Jul;160(3):261-268. doi: 10.1111/imm.13223.
3
Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.SARS-CoV-2 感染患者外周血淋巴细胞反应和细胞因子谱的纵向特征。
EBioMedicine. 2020 May;55:102763. doi: 10.1016/j.ebiom.2020.102763. Epub 2020 Apr 18.
4
Clinical Features of COVID-19-Related Liver Functional Abnormality.新型冠状病毒病相关肝功能异常的临床特征。
Clin Gastroenterol Hepatol. 2020 Jun;18(7):1561-1566. doi: 10.1016/j.cgh.2020.04.002. Epub 2020 Apr 10.
5
COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies.新型冠状病毒肺炎与肝功能障碍：当前见解及新出现的治疗策略
J Clin Transl Hepatol. 2020 Mar 28;8(1):18-24. doi: 10.14218/JCTH.2020.00018. Epub 2020 Mar 30.
6
COVID-19: immunopathology and its implications for therapy.新型冠状病毒肺炎：免疫病理学及其治疗意义。
Nat Rev Immunol. 2020 May;20(5):269-270. doi: 10.1038/s41577-020-0308-3.
7
Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19).COVID-19 患者的皮质类固醇治疗。
Med J Aust. 2020 May;212(9):416-420. doi: 10.5694/mja2.50577. Epub 2020 Apr 8.
8
Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now?2019冠状病毒病（COVID-19）中的肝脏和胃肠道受累：我们目前了解到了什么？
Arab J Gastroenterol. 2020 Mar;21(1):3-8. doi: 10.1016/j.ajg.2020.03.002. Epub 2020 Apr 3.
9
Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study.85 例武汉 COVID-19 死亡病例的临床特征。一项回顾性观察研究。
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379. doi: 10.1164/rccm.202003-0543OC.
10
Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China.COVID-19 患者的肝损伤：来自中国武汉市单个中心的 115 例回顾性分析。
Liver Int. 2020 Sep;40(9):2095-2103. doi: 10.1111/liv.14455. Epub 2020 Apr 28.
Zotero 插件